The PERK Branch of the Unfolded Protein Response Promotes DLL4 Expression by Activating an Alternative Translation Mechanism.

DLL4 (delta like ligand 4) IRES (internal ribosome entry site) PERK (PKR-Like endoplasmic reticulum kinase) UPR (unfolded protein response) angiogenesis endoplasmic reticulum stress hypoxia

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
25 Jan 2019
Historique:
received: 03 12 2018
revised: 15 01 2019
accepted: 22 01 2019
entrez: 30 1 2019
pubmed: 30 1 2019
medline: 30 1 2019
Statut: epublish

Résumé

Delta-like 4 (DLL4) is a pivotal endothelium specific Notch ligand that has been shown to function as a regulating factor during physiological and pathological angiogenesis. DLL4 functions as a negative regulator of angiogenic branching and sprouting. Interestingly,

Identifiants

pubmed: 30691003
pii: cancers11020142
doi: 10.3390/cancers11020142
pmc: PMC6406545
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Annu Rev Biochem. 1999;68:913-63
pubmed: 10872469
Mol Cell. 2000 Apr;5(4):607-16
pubmed: 10882097
Mol Cell Biol. 2000 Dec;20(23):8635-42
pubmed: 11073965
J Mol Biol. 2001 Jun 29;310(1):111-26
pubmed: 11419940
Differentiation. 2001 Dec;69(2-3):135-44
pubmed: 11798067
Am J Physiol Cell Physiol. 2002 May;282(5):C947-70
pubmed: 11940508
Mol Cell. 2003 Mar;11(3):757-71
pubmed: 12667457
J Cell Biol. 2003 Jun 23;161(6):1163-77
pubmed: 12810700
J Virol. 1992 Oct;66(10):5805-14
pubmed: 1382142
RNA. 2004 Feb;10(2):287-98
pubmed: 14730027
J Biol Chem. 2004 Apr 30;279(18):18717-26
pubmed: 14764596
Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15949-54
pubmed: 15520367
Protein Sci. 2005 Jun;14(6):1438-46
pubmed: 15883184
Cell Mol Life Sci. 2005 Jun;62(11):1267-74
pubmed: 15905964
EMBO J. 2005 Oct 5;24(19):3470-81
pubmed: 16148948
Cancer Res. 2005 Oct 1;65(19):8690-7
pubmed: 16204037
RNA. 2006 May;12(5):851-61
pubmed: 16540693
Science. 2006 May 12;312(5775):902-6
pubmed: 16690864
Mol Cell Biol. 2006 Dec;26(24):9517-32
pubmed: 17030613
Exp Cell Res. 2007 Jan 1;313(1):1-9
pubmed: 17045587
Cell Cycle. 2006 Oct;5(20):2401-13
pubmed: 17102617
Nature. 2006 Dec 21;444(7122):1032-7
pubmed: 17183313
Development. 2007 Mar;134(5):839-44
pubmed: 17251261
Circ Res. 2007 Feb 16;100(3):305-8
pubmed: 17255526
Nature. 2007 Feb 15;445(7129):781-4
pubmed: 17259972
Nature. 2007 Feb 15;445(7129):776-80
pubmed: 17259973
Mol Biol Cell. 2007 Apr;18(4):1302-11
pubmed: 17287399
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3219-24
pubmed: 17296940
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3225-30
pubmed: 17296941
Blood. 2007 Jun 1;109(11):4753-60
pubmed: 17311993
Nat Rev Cancer. 2007 May;7(5):327-31
pubmed: 17457300
Oncogene. 2008 Feb 14;27(8):1033-5
pubmed: 17767196
Mol Biol Cell. 2007 Dec;18(12):5048-59
pubmed: 17898077
Nucleic Acids Res. 2008 Apr;36(7):2434-45
pubmed: 18304943
PLoS One. 2008 Aug 27;3(8):e3078
pubmed: 18728783
J Biol Chem. 2008 Dec 26;283(52):36542-52
pubmed: 18984585
RNA. 2009 Feb;15(2):249-54
pubmed: 19144909
Nucleic Acids Res. 2009 Sep;37(16):5267-78
pubmed: 19561198
Br J Cancer. 2009 Nov 17;101(10):1749-57
pubmed: 19844231
Cell Death Differ. 2010 Apr;17(4):719-29
pubmed: 19893574
Nucleic Acids Res. 2010 Jan;38(Database issue):D131-6
pubmed: 19917642
Semin Cell Dev Biol. 2010 Aug;21(6):638-45
pubmed: 20226260
J Biol Chem. 2010 May 28;285(22):17098-111
pubmed: 20338999
EMBO J. 2010 Jun 2;29(11):1865-76
pubmed: 20453831
Cancer Res. 2010 Jul 15;70(14):6026-35
pubmed: 20587522
Curr Opin Cell Biol. 2010 Oct;22(5):617-25
pubmed: 20817428
BMC Cancer. 2010 Nov 23;10:641
pubmed: 21092311
Asian Pac J Cancer Prev. 2011;12(1):215-8
pubmed: 21517260
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
Blood. 2012 Jan 5;119(1):262-72
pubmed: 22058113
Mol Cell. 2011 Nov 18;44(4):660-6
pubmed: 22099312
Cancer Res. 2012 Oct 15;72(20):5396-406
pubmed: 22915762
Biochem J. 2013 Jan 15;449(2):543-53
pubmed: 23106379
Med Oncol. 2013 Mar;30(1):390
pubmed: 23275120
Histol Histopathol. 2013 Feb;28(2):277-84
pubmed: 23275310
Biochim Biophys Acta. 2013 Oct;1833(10):2165-75
pubmed: 23665047
Nucleic Acids Res. 2013 Sep;41(17):8308-18
pubmed: 23821664
Nucleic Acids Res. 2013 Sep;41(17):7997-8010
pubmed: 23851566
Cancer Cell. 2013 Sep 9;24(3):318-30
pubmed: 24029231
Biochim Biophys Acta. 2015 Jul;1849(7):887-97
pubmed: 25257759
J Virol. 1985 Jun;54(3):894-8
pubmed: 2582150
Cancer Discov. 2015 Jun;5(6):586-97
pubmed: 25977222
Oncotarget. 2015 Nov 24;6(37):39924-40
pubmed: 26498689
Sci Signal. 2016 May 03;9(426):ra44
pubmed: 27141928
Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25
pubmed: 27461391
Biochem Biophys Res Commun. 2016 Oct 14;479(2):365-371
pubmed: 27644878
Nucleic Acids Res. 2017 Jan 25;45(2):513-526
pubmed: 27923997
Nat Struct Mol Biol. 2017 Oct 5;24(10):789-790
pubmed: 28981072
Int J Biochem Cell Biol. 2017 Dec;93:46-51
pubmed: 29107182
Nat Rev Mol Cell Biol. 2018 Mar;19(3):158-174
pubmed: 29165424
Nat New Biol. 1973 Mar 14;242(115):35-8
pubmed: 4512006
Science. 1984 Mar 23;223(4642):1296-9
pubmed: 6199844
EMBO J. 1994 Apr 1;13(7):1673-81
pubmed: 8157006
Nucleic Acids Res. 1993 May 25;21(10):2315-22
pubmed: 8506129
Nature. 1996 Apr 4;380(6573):435-9
pubmed: 8602241
Nature. 1996 Apr 4;380(6573):439-42
pubmed: 8602242

Auteurs

Manon Jaud (M)

Inserm UMR1037, CRCT (Cancer Research Center of Toulouse), CNRS ERL5294, Université Toulouse III Paul-Sabatier, F-31037 Toulouse, France. manon.jaud@inserm.fr.

Céline Philippe (C)

Inserm UMR1037, CRCT (Cancer Research Center of Toulouse), CNRS ERL5294, Université Toulouse III Paul-Sabatier, F-31037 Toulouse, France. c.philippe@qmul.ac.uk.

Loic Van Den Berghe (L)

Inserm UMR1037, CRCT (Cancer Research Center of Toulouse), CNRS ERL5294, Université Toulouse III Paul-Sabatier, F-31037 Toulouse, France. Loic.Vandenberghe@inserm.fr.
Vectorology Plateform, Technological pole CRCT, F-31037 Toulouse, France. Loic.Vandenberghe@inserm.fr.

Christèle Ségura (C)

Inserm UMR1037, CRCT (Cancer Research Center of Toulouse), CNRS ERL5294, Université Toulouse III Paul-Sabatier, F-31037 Toulouse, France. christele.segura@inserm.fr.
Vectorology Plateform, Technological pole CRCT, F-31037 Toulouse, France. christele.segura@inserm.fr.

Laurent Mazzolini (L)

Inserm UMR1037, CRCT (Cancer Research Center of Toulouse), CNRS ERL5294, Université Toulouse III Paul-Sabatier, F-31037 Toulouse, France. laurent.mazzolini@inserm.fr.

Stéphane Pyronnet (S)

Inserm UMR1037, CRCT (Cancer Research Center of Toulouse), CNRS ERL5294, Université Toulouse III Paul-Sabatier, F-31037 Toulouse, France. stephane.pyronnet@inserm.fr.

Henrik Laurell (H)

Inserm UMR1048, I2MC (Institut des Maladies Métaboliques et Cardiovasculaires), Toulouse, France. henrik.laurell@inserm.fr.

Christian Touriol (C)

Inserm UMR1037, CRCT (Cancer Research Center of Toulouse), CNRS ERL5294, Université Toulouse III Paul-Sabatier, F-31037 Toulouse, France. christian.touriol@inserm.fr.

Classifications MeSH